Business Plans and Matters Related to Growth Potential
Filed with TSE · · 66 pages · English
Modalis Therapeutics Corporation on 6ix
Earlier from Modalis Therapeutics
- Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD
- Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.
- Modalis Therapeutics - MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a has been granted Orphan Drug Designation in the US by the Food and Drug Administration
- Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).
- Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)
Later from Modalis Therapeutics
- Consolidated Financial Results for the Six Months Ended June 30, 2026 [Japanese GAAP]
- Exegenesis Bio and Modalis Collaborate to Advance MDL-201 for Duchenne Muscular Dystrophy
Follow Modalis Therapeutics into a list and get an email when it puts out news.
Follow Modalis Therapeutics